Physician profile
Amanda Wallace
NPI 1154844041
$3,317.20
in general payments reported to CMS, 2019-2025
28 companies · $25.00 in 2025
The $25.00 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,426 · 2022: $1,340 · 2023: $491 · 2024: $35.23 · 2025: $25.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $551.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $551.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $573.58 | 2021-2023 | Farxiga |
| Novo Nordisk INC | $439.19 | 2021-2023 | Ozempic, Rybelsus |
| Lilly USA, LLC | $397.06 | 2021-2023 | Jardiance, Mounjaro |
| Abbott Laboratories | $380.49 | 2021-2023 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $301.08 | 2021-2023 | |
| Abbvie INC. | $233.31 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.44 | 2021-2023 | Jardiance |
| Esperion Therapeutics, INC. | $105.48 | 2021-2022 | |
| Dexcom, INC. | $77.13 | 2021-2023 | Dexcom G6 Transmitter |
| Ferring Pharmaceuticals INC. | $73.05 | 2023-2025 | Rebyota |
| Alexion Pharmaceuticals, INC. | $62.99 | 2022-2023 | Strensiq |
| Medtronic, INC. | $62.64 | 2021-2023 | Inpen Smart Insulin Delivery System |
| Merck Sharp & Dohme LLC | $59.49 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $59.33 | 2021-2022 | |
| Ibsa Pharma INC. | $54.66 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $53.75 | 2022 | |
| Insulet Corporation | $51.66 | 2021-2022 | |
| Ultragenyx Pharmaceutical INC. | $31.01 | 2021-2022 | |
| Amgen INC. | $26.87 | 2022-2023 | Evenity, Prolia |
| Amarin Pharma, INC. | $24.67 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $23.69 | 2021 | |
| Alkermes, INC. | $17.59 | 2023 | Vivitrol |
| Corcept Therapeutics | $16.83 | 2021 | |
| Amryt Pharma Holdings LTD | $15.22 | 2022 | |
| Braeburn INC. | $14.60 | 2024 | Brixadi |
| Zealand Pharma US, INC. | $14.29 | 2022 | |
| Indivior INC. | $13.57 | 2023 | Sublocade |
| Bayer Healthcare Pharmaceuticals INC. | $11.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Wallace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.